Literature DB >> 32209506

Treatment strategies and prognosis for initially unresectable ruptured hepatocellular carcinoma: a single-center experience in 94 patients.

Chun Zhou1, Qing-Quan Zu1, Xing-Long Liu1, Bin Wang1, Chun-Gao Zhou1, Hai-Bin Shi1, Sheng Liu1.   

Abstract

PURPOSE: To identify the treatment options and prognostic factors for patients with initially unresectable ruptured hepatocellular carcinoma (HCC).
METHODS: Between June 2012 to December 2016, 94 consecutive patients with initially unresectable ruptured HCC were analyzed retrospectively in this study. Patients were followed until December 2017. Predictors of short-term (≤30 days) and long-term (>30 days) survival were identified by using logistic regression model and Cox proportional hazard model, respectively.
RESULTS: Of the 94 patients, initial hemostasis treatment was achieved by transarterial embolization (TAE) in 59 patients, surgical hemostasis in 14, and conservative treatment in 21. Twenty-five (26.6%) patients died within 30 d after tumor rupture. In the multivariate analysis, patients treated with aggressive initial treatment strategies (TAE or surgical hemostasis) (P < 0.001) or those with better Child-Pugh class (P = 0.003) and absence of shock on admission (P = 0.001) had a better chance of short-term survival. Of the 69 patients who survived more than 30 days after initial treatment, the median survival time was 268 d. In the multivariate analysis, among the 69 who survived, early modified LCSGJ stage (P = 0.003) and staged hepatectomy as definitive treatment (P < 0.001) were significant predictors of increased long-term survival.
CONCLUSION: Short-term survival of patients with initially unresectable ruptured HCC could achieve with better Child-Pugh class, absence of shock and aggressive initial treatment strategies. After survived the emergency phase of tumor rupture, long-term survival was significantly increased with early modified LCSGJ stage and staged hepatectomy therapy.

Entities:  

Mesh:

Year:  2020        PMID: 32209506      PMCID: PMC7239369          DOI: 10.5152/dir.2019.19049

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  24 in total

Review 1.  Spontaneous ruptured hepatocellular carcinoma.

Authors:  Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Eiji Uchida
Journal:  Hepatol Res       Date:  2015-03-02       Impact factor: 4.288

Review 2.  Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: A systematic review.

Authors:  Demetrios Moris; Jeffery Chakedis; Steven H Sun; Gaya Spolverato; Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Eleftherios Spartalis; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2017-11-08       Impact factor: 3.454

3.  Multidisciplinary management of ruptured hepatocellular carcinoma.

Authors:  Andrzej K Buczkowski; Peter T W Kim; Stephen G Ho; David F Schaeffer; Sung I Lee; David A Owen; Alan H Weiss; Stephen W Chung; Charles H Scudamore
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

4.  Management of spontaneous rupture of hepatocellular carcinoma: single-center experience.

Authors:  C L Liu; S T Fan; C M Lo; W K Tso; R T Poon; C M Lam; J Wong
Journal:  J Clin Oncol       Date:  2001-09-01       Impact factor: 44.544

5.  Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.

Authors:  Thomas W T Leung; Amanda M Y Tang; Benny Zee; W Y Lau; Paul B S Lai; K L Leung; Joseph T F Lau; Simon C H Yu; Philip J Johnson
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

7.  Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey.

Authors:  Taku Aoki; Norihiro Kokudo; Yutaka Matsuyama; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2014-03       Impact factor: 12.969

8.  Management of spontaneously ruptured hepatocellular carcinoma and hemoperitoneum manifested as acute abdomen in the emergency room.

Authors:  Kuan-Chun Hsueh; Hsiu-Lung Fan; Teng-Wei Chen; De-Chuan Chan; Jyh-Cherng Yu; Shung-Sheng Tsou; Tzu-Ming Chang; Chung-Bao Hsieh
Journal:  World J Surg       Date:  2012-11       Impact factor: 3.352

9.  Is Emergency Transcatheter Hepatic Arterial Embolization Suitable for Spontaneously Ruptured Hepatocellular Carcinoma in Child-Pugh C Cirrhosis?

Authors:  Wen-Zhe Fan; Ying-Qiang Zhang; Wang Yao; Yu Wang; Guo-Sheng Tan; Yong-Hui Huang; Jian-Yong Yang; Jia-Ping Li
Journal:  J Vasc Interv Radiol       Date:  2017-12-14       Impact factor: 3.464

10.  Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study.

Authors:  Hiroyuki Kirikoshi; Satoru Saito; Masato Yoneda; Koji Fujita; Hironori Mawatari; Takashi Uchiyama; Takuma Higurashi; Kento Imajo; Takashi Sakaguchi; Kazuhiro Atsukawa; Aya Sawabe; Akira Kanesaki; Hirokazu Takahashi; Yasunobu Abe; Masahiko Inamori; Noritoshi Kobayashi; Kensuke Kubota; Norio Ueno; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2009-04-30       Impact factor: 3.067

View more
  2 in total

1.  Development and Validation of Artificial Neural Networks for Survival Prediction Model for Patients with Spontaneous Hepatocellular Carcinoma Rupture After Transcatheter Arterial Embolization.

Authors:  Yiwen Qiu; Tao Wang; Xianwei Yang; Shu Shen; Yi Yang; Wentao Wang
Journal:  Cancer Manag Res       Date:  2021-09-27       Impact factor: 3.989

Review 2.  Ruptured Hepatocellular Carcinoma: What Do Interventional Radiologists Need to Know?

Authors:  Jingxin Yan; Ting Li; Manjun Deng; Haining Fan
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.